Free shipping on all orders over $ 500

BCPyr

Cat. No. M21293
BCPyr Structure
Size Price Availability
Free Delivery on orders over USD 500 Bulk Inquiry?
Quality Control & Documentation
Biological Activity

BCPyr is a new candidate BTK degradation agent (DC50 = 800 nM).

Chemical Information
Molecular Weight 1082.20
Formula C58H65F2N11O8
CAS Number 2669844-82-8
Solubility (25°C) N/A
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Boxing Zhu, et al. J Chem Phys. Radiative cooling rates of substituted PAH ions

[2] Mai Su, et al. Sci Total Environ. Levels, profiles and potential human health risks of brominated and parent polycyclic aromatic hydrocarbons in soils around three different types of industrial areas in China

[3] Jing Zheng, et al. Environ Sci Technol. Marine and Anthropogenic Bromopyrroles Alter Cellular Ca2+ Dynamics of Murine Cortical Neuronal Networks by Targeting the Ryanodine Receptor and Sarco/Endoplasmic Reticulum Ca2+-ATPase

[4] Ranran Liu, et al. Environ Int. Field study of PAHs with their derivatives emitted from e-waste dismantling processes and their comprehensive human exposure implications

[5] Matthew D Hall, et al. J Struct Biol. The fate of platinum(II) and platinum(IV) anti-cancer agents in cancer cells and tumours

Related BTK Products
TAS5315

TAS5315 is a novel, irreversible covalent inhibitor of BTK for studies related to rheumatoid arthritis.
JS25 

JS25 is a selective and covalent inhibitor of BTK that inactivates BTK with an IC50 value of 5.8 nM by chelating Tyr551. JS25 inhibits cancer cells proliferation, pronounces cell death, and promotes murine xenograft model of Burkitt’s lymphoma. JS25 effectively crosses the blood-brain barrier.
BGB-8035 

BGB-8035 is an orally active, highly selective bruton's tyrosine kinase (BTK) inhibitor with IC50s of 1.1 nM, 99 nM, 621 nM for BTK, TEC, EGFR, respectively. BGB-8035 has antitumor and anti-arthritis activity. BGB-8035 has the potential for B-cell malignancies and autoimmune diseases research.
CHMFL-BTK-01 

CHMFL-BTK-01 (compound 9) is a highly selective irreversible BTK inhibitor, with an IC50 of 7 nM. CHMFL-BTK-01 (compound 9) potently inhibited BTK Y223 auto-phosphorylation.
BTK inhibitor 17 

BTK inhibitor 17 is a potent and orally active irreversible BTK inhibitor with an IC50 of 2.1 nM. BTK inhibitor 17 can be used for rheumatoid arthritis research.
  Catalog
Abmole Inhibitor Catalog




Keywords: BCPyr supplier, BTK, inhibitors, activators

 
Get to Know Us
Customer Support
Resources
Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.